玉屏风散联合常规西药治疗成人支气管哮喘的系统评价与Meta分析
该系统评价纳入20项RCT共1896例成人支气管哮喘患者,比较玉屏风散联合常规西药与单用常规西药的疗效。Meta分析显示联合组临床总有效率显著更高(RR=1.20),肺功能指标及ACT评分均显著改善,CD4+/CD8+比值无显著差异,安全性良好但不良事件报告不足。
要点
- 玉屏风散联合常规西药可显著提高成人哮喘临床总有效率(RR=1.20,95%CI 1.16–1.25)。
- 联合治疗显著改善FEV1、FVC、FEV1/FVC、PEF及ACT评分,SMD分别为1.32、1.78、1.09、1.15、1.80。
- CD4+/CD8+比值组间无统计学差异,安全性信号有限需高质量RCT进一步验证。
核心结论
- 玉屏风散联合常规西药可显著改善成人支气管哮喘患者的临床疗效、肺功能及症状控制。
- 因纳入研究方法学质量中等、地域受限及不良事件数据不足,结论需大样本双盲安慰剂对照RCT进一步验证。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA 2020,方案注册于PROSPERO(CRD420251172600)。
- 最终纳入20项RCT,共1896例参与者(干预组950例,对照组946例)。
- 使用Cochrane ROB 2.0评估偏倚风险,采用RevMan 5.4和Stata 18进行Meta分析、亚组分析及Meta回归。
主要发现
- 联合组临床总有效率显著高于对照组(RR=1.20,95%CI 1.16–1.25,P<0.001,I2=0.0%)。
- 肺功能指标FEV1、FVC、FEV1/FVC、PEF及ACT评分均显著改善,SMD分别为1.32、1.78、1.09、1.15、1.80,均P<0.05。
- CD4+/CD8+T淋巴细胞亚群比值组间无统计学差异(SMD=0.50,95%CI -0.44–1.44,P=0.301)。
- 亚组分析及Meta回归显示疗程(P=0.03)和发表年份(P=0.043)是异质性主要来源。
- 仅2项研究报告轻度不良事件(如胃肠不适、口干),组间发生率无显著差异,无严重不良事件。
关键数值与推荐
- 联合组临床总有效率为86.8%,对照组为72.3%,绝对危险度降低(ARR)为14.5%。
- 纳入研究为随机对照试验,干预为玉屏风散联合常规西药对比单用常规西药,对象为成人支气管哮喘患者。
临床怎么用
- 在常规西药治疗基础上联合玉屏风散可能提高成人支气管哮喘的临床总有效率并改善肺功能与症状控制。
- 联合治疗安全性信号有限,仅少数轻度不良事件报告,临床使用时应关注胃肠不适及口干等反应。
- 因证据质量中等且异质性受疗程与发表年份影响,应用时需结合患者具体情况并期待更高质量研究验证。
局限性
- 纳入研究方法学质量中等,存在偏倚风险。
- 研究地域受限,可能影响结果外推性。
- 不良事件数据不足,安全性评价受限。
- 研究间存在异质性,主要来源为疗程和发表年份。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Yupingfeng Powder (YPF), a classical Chinese herbal formula composed of Astragalus membranaceus, Atractylodes macrocephala, and Saposhnikovia divaricata, has demonstrated potential efficacy in the treatment of adult bronchial asthma when combined with conventional biomedical therapy (CBT), as indicated by multiple recent clinical studies. However, existing research is limited by small sample sizes, inconsistent methodological quality, and non-uniform syndrome differentiation, resulting in insufficient evidence strength. Moreover, traditional meta-analysis methods struggle to address study heterogeneity, and its definitive efficacy remains inadequately validated. OBJECTIVE: To systematically evaluate the clinical efficacy and safety of YPF combined with CBT in the treatment of adult bronchial asthma, and to clarify the heterogeneity sources. METHODS: Strictly adhering to the PRISMA 2020 guidelines, the study protocol was registered in PROSPERO (registration number: CRD420251172600). A systematic search was conducted in seven databases (PubMed, Embase, Cochrane Library, China, etc., up to 20 October 2025), and randomized controlled trials (RCTs) comparing YPF+CBT with CBT alone in adults with bronchial asthma were included. The Cochrane ROB 2.0 tool was used to assess the risk of bias, and meta-analysis was performed using RevMan 5.4 and Stata 18 software. Subgroup analysis and Meta regression were employed to explore the sources of heterogeneity. RESULTS: A total of 20 RCTs were ultimately included, involving 1,896 participants (950 in the intervention group and 946 in the control group). The meta-analysis revealed that the YPF+CBT group demonstrated significantly higher clinical overall response rate compared to the CBT group [risk ratio (RR) = 1.20, 95% CI (1.16, 1.25), P < 0.001, I2 = 0.0%]. Significant improvements were observed in pulmonary function parameters (FEV1, FVC, FEV1/FVC, PEF) and asthma control test (ACT) scores [SMD were 1.32, 1.78, 1.09, 1.15, and 1.80, respectively, all P < 0.05]. No statistically significant difference was found in the CD4+/CD8+T lymphocyte subset ratio between the two groups [SMD = 0.50, 95%CI(-0.44, 1.44), P = 0.301]. Subgroup analysis and meta-regression confirmed that treatment duration (P = 0.03) and study year (P = 0.043) were the primary sources of heterogeneity. In terms of safety, only two studies reported mild adverse events (e.g., gastrointestinal discomfort, dry mouth), with no significant difference in incidence between the groups and no serious adverse events. Clinical significance analysis showed that the clinical overall response rate in the YPF+CBT group was 86.8%, which was compared to 72.3% in the CBT group, with an absolute risk reduction (ARR) of 14.5%, indicating clear clinical benefits of this combination therapy. CONCLUSION: YPF combined with CBT can significantly improve clinical efficacy, pulmonary function, and symptom control in adult bronchial asthma patients. However, due to limitations such as moderate methodological quality of the included studies, geographical constraints, and insufficient adverse event data, the conclusions require further validation through high-quality RCTs with large sample sizes, double-blind design, and placebo control. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=1172600, identifier CRD420251172600.
引用
- Zhang Q, Zhang N, Zheng Y, et al. Efficacy of Yupingfeng powder in the treatment of bronchial asthma in adults: a systematic review and meta-analysis. Front Pharmacol. 2026. PMID: 42147341. doi:10.3389/fphar.2026.1757474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。